Novartis Stock - Long-term growth targets and Thursday technical picture
18.06.2026 - 21:27:10 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 21:24 CET. Details in the imprint.
Novartis (CH0012005267) sets out medium-term growth ambitions while its shares hover around important technical reference points on Thursday. According to a recent Form 6-K filed with the SEC, the company targets a constant-currency sales compound annual growth rate of 5-6% for 2025-2030.
All news and key data on Novartis stock
For more regulatory filings, news and background on Novartis stock, our topic page and the company's investor-relations portal provide a detailed starting point.
What the SEC filing shows
In the recent Form 6-K, Novartis outlined a constant-currency sales CAGR ambition of 5-6% for the period 2025-2030, highlighting confidence in its growth drivers and pipeline.
The document also referenced eight de-risked, in-market assets with multi-billion-dollar peak sales potential and more than 30 potential high-value medicines in the broader pipeline.
Thursday's chart and technical levels
On Thursday, Novartis shares listed in New York last traded around $147.59, leaving the stock up roughly 27% over the past 12 months, according to recent quote data.
This level places the US-listed shares close to the upper area of their one-year trading range, suggesting that the stock has seen a robust upward trend into mid-2026.
The product portfolio behind the stock
Novartis generates its revenue primarily from prescription medicines across therapeutic areas such as cardiovascular disease, immunology, neuroscience and oncology, with treatments like Entresto for heart failure and Cosentyx for autoimmune conditions among its key branded drugs.
Where the stock trades today
Novartis shares trade on the New York Stock Exchange under the ticker NVS at $147.59 as of 06/18/2026, 14:01 ET.
Key facts on Novartis stock
- Company: Novartis AG
- ISIN: CH0012005267
- WKN: 904278
- Ticker: NVS
- Venue: NYSE
- Price (as of 06/18/2026, 14:01 ET): 147.59 USD
- Market cap: 313,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI, Stoxx Europe 50
- Next earnings date: 07/16/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
